Antibodies with Infinite Affinity
Antibodies with Infinite Affinity
批准号:
7563967
负责人:
CLAUDE F. MEARES
金额:
$28.88万
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-06-01 至 2011-02-28
关键词:
AddressAffectAffinityAntibodiesAntibody AffinityAntibody SpecificityAntigen-Antibody ComplexAntigensB-Cell LymphomasB-LymphocytesBehaviorBindingBinding SitesBiologicalCarcinoembryonic AntigenCell Culture TechniquesCell Surface ProteinsCell surfaceCellsColorectal CancerComplexCross ReactionsDevelopmentDiagnosisDissociationDrug KineticsEngineeringEventExhibitsFDA approvedGoalsGrantHLA-DR AntigensHumanImageImmunoglobulin FragmentsKnowledgeLeadLifeLigandsLinkMS4A1 geneMalignant NeoplasmsMeasuresMembrane MicrodomainsModificationMolecularMolecular TargetMonoclonal Antibody Lym-1Neoplasm AntibodiesNormal tissue morphologyPTPRC genePenetrationPhotonsProceduresProcessPropertyProtein EngineeringProtein Tyrosine PhosphataseProteinsRadiation therapyReactionReagentResearch PersonnelRoche brand of rituximabSiteSolid NeoplasmSpecificityStructureSurfaceSurface Plasmon ResonanceSynthesis ChemistryTherapeutic antibodiesTimeTumor AntigensWorkY 90 Ibritumomab Tiuxetanbasecancer imagingchemical geneticschemical synthesiscrosslinkdesigndirected evolutionimprovedinnovationiodine-131-tositumomabprogramsreceptorresidencesmall moleculetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objectives of this project are to develop an innovative set of probe molecules for targeted diagnosis and therapy of human cancer. The preferred approach is to place an artificial receptor on a target cell, and then to load the receptor with a small molecule that delivers photons for imaging or radiation for therapy. This allows us to use the well-developed target selection available for antibodies, in concert with the rapid pharmacokinetics of small molecules. We add the important feature that the molecules studied here bind with infinite affinity: they selectively form complexes that do not dissociate. This allows maximum time on target, limited only by natural turnover processes.
It is a well-known problem in tumor targeting that conventional, reversibly-binding antibodies with high affinity do not penetrate efficiently beyond the surface of a tumor. This is usually called the binding-site barrier, and its basis is the long bound lifetime exhibited by a high-affinity antibody on its target. Weakly binding antibodies, or more usually their monovalent fragments, do not share this problem because they bind and dissociate frequently-but for the same reason, they do not remain in the tumor long enough to be effective. This paradoxical need for ligands of simultaneous low and high affinity significantly limits the efficacy of antibodies for imaging and above all for therapy of solid tumors. Selective binding without dissociation solves an important practical problem in probe capture for tumor targeting, but may also present an obstacle to efficacious distribution of the ligand throughout the tumor. A more subtle alternative, which should lead to far more effective tumor penetration of antitumor antibodies or engineered fragments, is to combine weak with infinite binding. If we begin with low-affinity antitumor antibodies and prepare constructs that can bind permanently, but only after many association-dissociation events, this should allow the constructs not only to permeate the tumor but also to eventually attach permanently to their targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bispecific Antibody Engineering for AML RIT
-
批准号:8270376
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2009
-
负责人:CLAUDE F. MEARES
-
依托单位:
Bispecific Antibody Engineering for AML RIT
-
批准号:7728874
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2009
-
负责人:CLAUDE F. MEARES
-
依托单位:
Bispecific Antibody Engineering for AML RIT
-
批准号:8076397
-
项目类别:
-
资助金额:$31.89万
-
财政年份:2009
-
负责人:CLAUDE F. MEARES
-
依托单位:
Pretargeted Antibodies with Infinite Affinity
-
批准号:6557062
-
项目类别:
-
资助金额:$24.07万
-
财政年份:2003
-
负责人:CLAUDE F. MEARES
-
依托单位:
Pretargeted Antibodies with Infinite Affinity
-
批准号:7050632
-
项目类别:
-
资助金额:$18.89万
-
财政年份:2003
-
负责人:CLAUDE F. MEARES
-
依托单位:
Pretargeted Antibodies with Infinite Affinity
-
批准号:6759287
-
项目类别:
-
资助金额:$19.39万
-
财政年份:2003
-
负责人:CLAUDE F. MEARES
-
依托单位:
Pretargeted Antibodies with Infinite Affinity
-
批准号:6889932
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2003
-
负责人:CLAUDE F. MEARES
-
依托单位:
BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
-
批准号:6308883
-
项目类别:
-
资助金额:$0.99万
-
财政年份:2000
-
负责人:CLAUDE F. MEARES
-
依托单位:
Antibody/chelate conjugates
-
批准号:6347310
-
项目类别:
-
资助金额:$18.05万
-
财政年份:2000
-
负责人:CLAUDE F. MEARES
-
依托单位:
ANTIBODY-CHELATE CONJUGATES
-
批准号:6295927
-
项目类别:
-
资助金额:$6.49万
-
财政年份:1998
-
负责人:CLAUDE F. MEARES
-
依托单位:
ANTIBODY-CHELATE CONJUGATES
-
批准号:6269341
-
项目类别:
-
资助金额:$16.14万
-
财政年份:1998
-
负责人:CLAUDE F. MEARES
-
依托单位:
BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
-
批准号:6281180
-
项目类别:
-
资助金额:$0.1万
-
财政年份:1998
-
负责人:CLAUDE F. MEARES
-
依托单位:
BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
-
批准号:6251499
-
项目类别:
-
资助金额:$1.1万
-
财政年份:1997
-
负责人:CLAUDE F. MEARES
-
依托单位:
ANTIBODY-CHELATE CONJUGATES
-
批准号:6236982
-
项目类别:
-
资助金额:$15.54万
-
财政年份:1997
-
负责人:CLAUDE F. MEARES
-
依托单位:
SMALL INSTRUMENTATION PROGRAM
-
批准号:3523042
-
项目类别:
-
资助金额:$4.4万
-
财政年份:1988
-
负责人:CLAUDE F. MEARES
-
依托单位:
Antibody/chelate conjugates
-
批准号:6254385
-
项目类别:
-
资助金额:$18.05万
-
财政年份:1988
-
负责人:CLAUDE F. MEARES
-
依托单位:
BIFUNCTIONAL CHELATING AGENTS IN TUMOR LOCALIZATION
-
批准号:6172225
-
项目类别:
-
资助金额:$18.34万
-
财政年份:1978
-
负责人:CLAUDE F. MEARES
-
依托单位:
PHOTOCHEMICAL & SPECTROSCOPIC PROBES OF RNA POLYMERASE
-
批准号:3273416
-
项目类别:
-
资助金额:$9.77万
-
财政年份:1978
-
负责人:CLAUDE F. MEARES
-
依托单位:
PHOTOCHEMICAL & SPECTROSCOPIC PROBES OF RNA POLYMERASE
-
批准号:3273421
-
项目类别:
-
资助金额:$8.8万
-
财政年份:1978
-
负责人:CLAUDE F. MEARES
-
依托单位:
Antibodies with Infinite Affinity
-
批准号:7216357
-
项目类别:
-
资助金额:$27.74万
-
财政年份:1978
-
负责人:CLAUDE F. MEARES
-
依托单位:
海外基金